The linearly decreasing convergence factor a. by Junhao Wei (6816803)

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Significant associations in GWAS. by Dai Nogimura (21445649)

Subjects:

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

Demonstration of decreased Aβ accumulation by DA-9601 treatment. by Mijung Lee (397790)

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

eQTL analysis of significant SNPs. by Dai Nogimura (21445649)

Subjects:

Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

“…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. by Xiaoqin Li (1399105)

Summary of significant single-arm time effect. by Wensheng Xiao (16557866)

Significant Decrease in Vessel Count of Trade Vessels in (a) Bosporus Strait and (b) Bab el-Mandeb Strait. by Cherryl Chico (20978829)

Task 2 one-way ANCOVA significant results. by Mucahit Gemici (21519313)

Task 1 two-way ANCOVA significant results. by Mucahit Gemici (21519313)

Effectiveness of the proposed method to decrease chloroplast contamination. by Gabriela Madrid (11871401)

Data Sheet 1_Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells.docx by Aida López Ruiz (21611177)

“…To address this need, in this work, we utilized a bioinspired, scalable, tunable platform to direct T-cell activation and decrease exhaustion during CAR T production.…”

Data Sheet 2_An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-m... by Christopher L. Reading (21236861)

Data Sheet 1_An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-m... by Christopher L. Reading (21236861)